BIO-TECHNE CORP shareholders Q4 2022

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q4 2022
NameSharesValueWeighting ↓
Fithian, LLC 42,979$3,562,10016.93%
Montanaro Asset Management Ltd 387,800$32,140,8645.23%
Brown Capital Management 3,301,492$273,627,6574.53%
Ownership Capital B.V. 2,678,672$222,008,3354.36%
Jackson Square Partners, LLC 1,927,141$159,721,4464.26%
Sandhill Capital Partners LLC 468,346$38,816,5414.14%
STONE RUN CAPITAL, LLC 85,060$7,049,7733.56%
DF DENT & CO INC 2,639,232$218,739,5163.27%
Spence Asset Management 224,162$18,5793.16%
Summit Creek Advisors LLC 261,412$21,665,8272.95%
Pembroke Management, LTD 323,976$26,851,1312.87%
AMERICAN CAPITAL MANAGEMENT INC 866,600$71,823,8082.81%
MAIRS & POWER INC 2,811,030$232,978,1492.80%
Aristotle Atlantic Partners, LLC 523,203$43,363,0652.43%
Select Equity Group, L.P. 7,153,947$592,919,1272.23%
GENEVA CAPITAL MANAGEMENT LLC 1,059,500$87,811,3601.97%
Handelsinvest Investeringsforvaltning 134,000$11,1061.75%
BAMCO INC /NY/ 5,519,062$457,419,8591.54%
SANDLER CAPITAL MANAGEMENT 171,280$14,195,6861.46%
Winslow Capital Management, LLC 3,147,924$260,899,9421.45%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q4 2022. To view BIO-TECHNE CORP's shareholder history, click here.